Propranolol
- Generic Name
- Propranolol
- Brand Names
- Hemangeol, Hemangiol, Inderal, Innopran
- Drug Type
- Small Molecule
- Chemical Formula
- C16H21NO2
- CAS Number
- 525-66-6
- Unique Ingredient Identifier
- 9Y8NXQ24VQ
- Background
Propranolol is a racemic mixture of 2 enantiomers where the S(-)-enantiomer has approximately 100 times the binding affinity for beta adrenergic receptors. Propranolol is used to treat a number of conditions but most commonly is used for hypertension.
Propranolol was granted FDA approval on 13 November 1967.
- Indication
Propranolol is indicated to treat hypertension. Propranolol is also indicated to treat angina pectoris due to coronary atherosclerosis, atrial fibrillation, myocardial infarction, migraine, essential tremor, hypertrophic subaortic stenosis, pheochromocytoma, and proliferating infantile hemangioma.
- Associated Conditions
- Akathisia caused by antipsychotic use, Angina Pectoris, Atrial Fibrillation, Cardiovascular Mortality, Essential Tremor, Gastroesophageal variceal hemorrhage prophylaxis, Hemangiomas, Hypertension, Migraine, Myocardial Infarction, Obstructive Hypertrophic Cardiomyopathy, Performance Anxiety, Pheochromocytoma, Proliferating Infantile Hemangioma, Supraventricular Arrhythmias, Tachyarrhythmia caused by Digitalis intoxication, Tachyarrhythmia caused by catecholamine excess, Thyroid Crisis, Thyrotoxicosis, Tremor caused by lithium, Ventricular Tachycardia (VT)
- Associated Therapies
- -
A Study in Healthy Young Men to Look at What Drives the Cardiovascular Effects After Dosing With Mirabegron.
- Conditions
- Interventions
- First Posted Date
- 2011-01-27
- Last Posted Date
- 2013-07-03
- Lead Sponsor
- Astellas Pharma Inc
- Target Recruit Count
- 12
- Registration Number
- NCT01284868
A Study of LY2216684 in Healthy Participants Receiving Albuterol or Propanolol
- Conditions
- Interventions
- First Posted Date
- 2010-12-20
- Last Posted Date
- 2019-01-29
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 48
- Registration Number
- NCT01263197
- Locations
- đșđž
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Evansville, Indiana, United States
Oral Propranolol Versus Placebo for Early Stages of Retinopathy of Prematurity: A Randomized and Prospective Study
- First Posted Date
- 2010-11-10
- Last Posted Date
- 2014-06-26
- Lead Sponsor
- Rambam Health Care Campus
- Target Recruit Count
- 20
- Registration Number
- NCT01238471
- Locations
- đźđ±
Nazareth Hospital, Nazareth, Israel
đźđ±Hadassah Medical Organization, Jerusalem, Israel
đźđ±Rambam Health Care Campus, Haifa, Israel
Study on the Effect of a Beta Blocker on Increased Sensitivity to Pain in Humans Caused by Opioids
- Conditions
- Interventions
- First Posted Date
- 2010-10-18
- Last Posted Date
- 2018-06-15
- Lead Sponsor
- Stanford University
- Target Recruit Count
- 10
- Registration Number
- NCT01222091
- Locations
- đșđž
Stanford University School of Medicine, Stanford, California, United States
Off Label Use of Propranolol for Infancy Hemangiomas
- First Posted Date
- 2010-09-29
- Last Posted Date
- 2014-11-11
- Lead Sponsor
- Hannover Medical School
- Target Recruit Count
- 72
- Registration Number
- NCT01211080
- Locations
- đ©đȘ
Pediatric Surgery, Kinderkrankenhaus Bult, Hannover, Germany
đ©đȘPediatric Surgery, Hannover Medical School, Hannover, Lower Saxony, Germany
đ©đȘKinderzentrum Klinikum Hildesheim, Hildesheim, Lower Saxony, Germany
Early Propranolol After Traumatic Brain Injury: Phase II
- First Posted Date
- 2010-09-15
- Last Posted Date
- 2016-05-13
- Lead Sponsor
- Cedars-Sinai Medical Center
- Target Recruit Count
- 10
- Registration Number
- NCT01202110
- Locations
- đșđž
Cedars-Sinai Medical Center, Los Angeles, California, United States
Evaluation of Propranolol's Effect on Pain and Inflammation.
- Conditions
- Interventions
- First Posted Date
- 2010-03-29
- Last Posted Date
- 2017-02-24
- Lead Sponsor
- Martin Angst
- Target Recruit Count
- 10
- Registration Number
- NCT01094574
- Locations
- đșđž
Stanford University School of Medicine, Stanford, California, United States
Pharmacokinetic Study in Patients With Chronic Kidney Disease and Healthy Volunteers
- Conditions
- Interventions
- First Posted Date
- 2010-03-16
- Last Posted Date
- 2013-05-30
- Lead Sponsor
- University of California, San Francisco
- Target Recruit Count
- 24
- Registration Number
- NCT01087749
- Locations
- đșđž
Clinical Reserach Center, UCSF, San Francisco,, California, United States
Safety and Efficacy of Propranolol in Newborns With Retinopathy of Prematurity
- First Posted Date
- 2010-03-03
- Last Posted Date
- 2012-11-27
- Lead Sponsor
- Azienda Ospedaliero, Universitaria Meyer
- Target Recruit Count
- 52
- Registration Number
- NCT01079715
- Locations
- đźđč
Neonatal Intensive Care Unit - Azienda Ospedaliero-Universitaria Meyer, Florence, Italy
đźđčNeonatal Intensive Care Unit - Fondazione IRCCS CĂ Granda, Ospedale Maggiore Policlinico, Milan, Italy
Study of Propranolol as Anti-Adhesive Therapy in Sickle Cell Disease (SCD)
- First Posted Date
- 2010-03-01
- Last Posted Date
- 2015-01-22
- Lead Sponsor
- Laura M. De Castro, MD
- Target Recruit Count
- 31
- Registration Number
- NCT01077921
- Locations
- đșđž
Duke University Medical Center, Durham, North Carolina, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.